Suppr超能文献

p53基因的P72R多态性易导致肥胖和代谢功能障碍。

The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction.

作者信息

Kung Che-Pei, Leu Julia I-Ju, Basu Subhasree, Khaku Sakina, Anokye-Danso Frederick, Liu Qin, George Donna L, Ahima Rexford S, Murphy Maureen E

机构信息

Molecular and Cellular Oncogenesis Program, The Wistar Institute, Philadelphia, PA 19104, USA.

Department of Genetics, The Perelman School at the University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.

出版信息

Cell Rep. 2016 Mar 15;14(10):2413-25. doi: 10.1016/j.celrep.2016.02.037. Epub 2016 Mar 3.

Abstract

p53 is well known for its tumor suppressor role, but this protein also has a poorly understood role in the regulation of metabolism. Human studies have implicated a common polymorphism at codon 72 of p53 in diabetic and pre-diabetic phenotypes. To understand this role, we utilized a humanized mouse model of the p53 codon 72 variants and monitored these mice following challenge with a high-fat diet (HFD). Mice with the arginine 72 (R72) variant of p53 developed more-severe obesity and glucose intolerance on a HFD, compared to mice with the proline 72 variant (P72). R72 mice developed insulin resistance, islet hypertrophy, increased infiltration of immune cells, and fatty liver disease. Gene expression analyses and studies with small-molecule inhibitors indicate that the p53 target genes Tnf and Npc1l1 underlie this phenotype. These results shed light on the role of p53 in obesity, metabolism, and inflammation.

摘要

p53因其肿瘤抑制作用而广为人知,但这种蛋白质在代谢调节中的作用却鲜为人知。人体研究表明,p53第72位密码子的常见多态性与糖尿病和糖尿病前期表型有关。为了解这一作用,我们利用了p53第72位密码子变体的人源化小鼠模型,并在高脂饮食(HFD)刺激后对这些小鼠进行监测。与携带脯氨酸72变体(P72)的小鼠相比,携带p53精氨酸72(R72)变体的小鼠在高脂饮食下出现了更严重的肥胖和葡萄糖不耐受。R72小鼠出现了胰岛素抵抗、胰岛肥大、免疫细胞浸润增加和脂肪肝疾病。基因表达分析和小分子抑制剂研究表明,p53靶基因Tnf和Npc1l1是这一表型的基础。这些结果揭示了p53在肥胖、代谢和炎症中的作用。

相似文献

1
The P72R Polymorphism of p53 Predisposes to Obesity and Metabolic Dysfunction.
Cell Rep. 2016 Mar 15;14(10):2413-25. doi: 10.1016/j.celrep.2016.02.037. Epub 2016 Mar 3.
4
Dynamic role of the codon 72 p53 single-nucleotide polymorphism in mammary tumorigenesis in a humanized mouse model.
Oncogene. 2019 May;38(18):3535-3550. doi: 10.1038/s41388-018-0630-4. Epub 2019 Jan 16.
5
Chronic inflammation exacerbates glucose metabolism disorders in C57BL/6J mice fed with high-fat diet.
J Endocrinol. 2013 Oct 28;219(3):195-204. doi: 10.1530/JOE-13-0160. Print 2013 Dec.
6
P53 codon 72 polymorphism in Taiwanese breast cancer patients.
Kaohsiung J Med Sci. 2013 May;29(5):259-64. doi: 10.1016/j.kjms.2012.09.004. Epub 2013 Feb 4.
7
Beraprost sodium, a stable prostacyclin analogue, improves insulin resistance in high-fat diet-induced obese mice.
J Endocrinol. 2012 Jun;213(3):285-91. doi: 10.1530/JOE-12-0014. Epub 2012 Mar 29.
8
Black elderberry extract attenuates inflammation and metabolic dysfunction in diet-induced obese mice.
Br J Nutr. 2015 Oct 28;114(8):1123-31. doi: 10.1017/S0007114515002962. Epub 2015 Aug 28.
9
The codon 72 polymorphism of p53 influences cell fate following nutrient deprivation.
Cancer Biol Ther. 2017 Jul 3;18(7):484-491. doi: 10.1080/15384047.2017.1323595. Epub 2017 May 5.
10
Taurine supplementation prevents morpho-physiological alterations in high-fat diet mice pancreatic β-cells.
Amino Acids. 2012 Oct;43(4):1791-801. doi: 10.1007/s00726-012-1263-5. Epub 2012 Mar 15.

引用本文的文献

1
p53 and TIGAR promote redox control to protect against metabolic dysfunction-associated steatohepatitis.
JHEP Rep. 2025 Mar 20;7(7):101397. doi: 10.1016/j.jhepr.2025.101397. eCollection 2025 Jul.
3
Endogenous p53 inhibitor TIRR dissociates systemic metabolic health from oncogenic activity.
Cell Rep. 2024 Jun 25;43(6):114337. doi: 10.1016/j.celrep.2024.114337. Epub 2024 Jun 9.
4
Understanding the complexity of p53 in a new era of tumor suppression.
Cancer Cell. 2024 Jun 10;42(6):946-967. doi: 10.1016/j.ccell.2024.04.009. Epub 2024 May 9.
6
Circular RNAs, Noncoding RNAs, and N6-methyladenosine Involved in the Development of MAFLD.
Noncoding RNA. 2024 Feb 5;10(1):11. doi: 10.3390/ncrna10010011.
8
Emerging insights into ethnic-specific TP53 germline variants.
J Natl Cancer Inst. 2023 Oct 9;115(10):1145-1156. doi: 10.1093/jnci/djad106.
10
p53 Arg72Pro polymorphism, adiposity status, and cancer risk: Two case-cohorts within a Japanese prospective study.
Cancer Sci. 2022 Dec;113(12):4385-4393. doi: 10.1111/cas.15572. Epub 2022 Sep 24.

本文引用的文献

1
Are pharmacogenomic biomarkers an effective tool to predict taxane toxicity and outcome in breast cancer patients? Literature review.
Cancer Chemother Pharmacol. 2015 Oct;76(4):679-90. doi: 10.1007/s00280-015-2818-4. Epub 2015 Jul 22.
2
Gene polymorphisms in the folate metabolism and their association with MTX-related adverse events in the treatment of ALL.
Tumour Biol. 2015 Jul;36(7):4913-21. doi: 10.1007/s13277-015-3602-0. Epub 2015 May 30.
3
Identification of TRIML2, a novel p53 target, that enhances p53 SUMOylation and regulates the transactivation of proapoptotic genes.
Mol Cancer Res. 2015 Feb;13(2):250-62. doi: 10.1158/1541-7786.MCR-14-0385. Epub 2014 Sep 25.
4
Nonalcoholic fatty liver disease: A main driver of insulin resistance or a dangerous liaison?
Biochim Biophys Acta. 2014 Nov;1842(11):2329-2343. doi: 10.1016/j.bbadis.2014.08.004. Epub 2014 Aug 14.
5
Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
World J Gastroenterol. 2014 Jul 21;20(27):9072-89. doi: 10.3748/wjg.v20.i27.9072.
6
Tumor suppressor p53 cooperates with SIRT6 to regulate gluconeogenesis by promoting FoxO1 nuclear exclusion.
Proc Natl Acad Sci U S A. 2014 Jul 22;111(29):10684-9. doi: 10.1073/pnas.1411026111. Epub 2014 Jul 9.
7
Obesity and cancer--mechanisms underlying tumour progression and recurrence.
Nat Rev Endocrinol. 2014 Aug;10(8):455-465. doi: 10.1038/nrendo.2014.94. Epub 2014 Jun 17.
8
On the evolutionary origins of obesity: a new hypothesis.
Endocrinology. 2014 May;155(5):1573-88. doi: 10.1210/en.2013-2103. Epub 2014 Feb 26.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验